Search for a command to run...
<h3>Background and Importance</h3> Anticholinergic burden (ACB) is associated with several adverse outcomes, including cognitive decline, falls, and prolonged hospital stays. Despite the known harms, there remains a high prevalence of patients with a problematic ACB from their medications. As such, it is unclear how aware healthcare professionals (HCPs) are of ACB and HCPs’ abilities to identify and manage ACB-related issues in practice. <h3>Aim and Objectives</h3> To explore the views and knowledge of HCPs regarding ACB. <h3>Material and Methods</h3> An anonymous online survey was piloted with various HCP types and then distributed to HCPs via email and social media between March and August 2025. Descriptive statistics were performed on all survey questions, which included multiple choice and Likert scale questions. <h3>Results</h3> A total of 250 valid responses were received, from pharmacists (81.6%), nurses (7.2%), doctors (4.4%), and other HCPs (6.8%). Most respondents agreed that identifying anticholinergic medications is important for patient safety (97.6%), and that they can play a role in identifying anticholinergic medications (97.6%) and managing ACB (90.7%). However, a large proportion were <i>‘slightly’</i> or ‘<i>not at all’</i> confident in their ACB knowledge (40%), identifying strong anticholinergic medications (32%), and calculating an ACB score (50.4%). While nearly two-thirds indicated that identifying potential anticholinergic side effects is a priority in their day-to-day roles (65.9%), over one third were <i>‘slightly’</i> or <i>‘not at all’</i> confident in their ability to recognise adverse anticholinergic effects (36.1%). Nearly all reported that being informed of an ACB score would impact their approach to care (98%), but only half were aware of ACB scoring systems (50.8%); among these, 48% reported seldom use, 6.3% reported once-off use, and 20.5% reported never using them in practice. While nearly two-thirds were aware of steps that can be taken to reduce ACB (64.7%), 92% indicated they would like additional training to identify anticholinergic side effects and ACB in their patients. <h3>Conclusion and Relevance</h3> This study has uniquely highlighted deficiencies in HCPs’ knowledge and abilities to manage ACB. The findings demonstrate a need for further ACB education and training, particularly enhanced awareness regarding ACB scoring systems, which should aid HCPs in identifying patients with problematic ACB and ultimately help reduce patient harm. <h3>Conflict of Interest</h3> No conflict of interest